Zogenix's seizure drug filing fails to pass U.S. FDA scrutiny
The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy.
from Reuters: Health News https://reut.rs/2InSDjJ
http://bit.ly/2zwRqiM